Relationship between arm-to-leg and limbs-to-trunk body composition ratio and cardiovascular disease risk factors

Sunmi Jung, Jihyun Park & Young-Gyun Seo

We aimed to analyze the relationship of the distribution of body fat mass (FM) and fat-free mass (FFM) in the limbs and trunk with the prevalence of cardiovascular disease risk factors (CVD-RF). In total, 13,032 adults were selected from the KNHANES (2008–2011). The prevalence of hypertension, diabetes mellitus (DM), dyslipidemia, and metabolic syndrome (MetS) according to the arm-to-leg ratio and limbs-to-trunk ratio for FM and FFM was compared, respectively. The higher the arm-to-leg FM ratio, the higher the prevalence of CVD-RF (DM-male-OR 7.04, 95% CI 4.22–11.74; DM-female-OR 10.57, 95% CI 5.80–19.26; MetS-male-OR 4.47, 95% CI 3.41–5.86; MetS-female-OR 8.73, 95% CI 6.38–11.95). The higher the limbs-to-trunk FM ratio, the higher the prevalence of DM (DM-male-OR 0.12, 95% CI 0.06–0.23; DM-female-OR 0.12, 95% CI 0.06–0.23; MetS-male-OR 0.06, 95% CI 0.04–0.08; MetS-female-OR 0.02, 95% CI 0.01–0.04), the higher the limbs-to-trunk FFM ratio (DM-male-OR 0.19, 95% CI 0.11–0.31; DM-female-OR 0.46, 95% CI 0.30–0.70; MetS-male-OR 0.39, 95% CI 0.31–0.50; MetS-female-OR 0.62, 95% CI 0.50–0.78), and the higher the arm-to-leg FFM ratio (MetS-male-OR 0.75, 95% CI 0.59–0.94; MetS-female-OR 0.73, 95% CI 0.58–0.92), the lower the prevalence of CVD-RF. The higher the FM of the legs compared to the arms, FFM of the arms compared to the legs, and FM or FFM of the limbs compared to the trunk, the lower the prevalence of CVD-RF.

The prevalence of cardiovascular disease (CVD) and metabolic syndrome (MetS) is increasing worldwide. MetS is a chronic metabolic disorder that involves a combination of CVD risk factors (CVD-RF) including high triglyceride (TG) levels, low high-density lipoprotein cholesterol (HDL-C) levels, high blood pressure (BP), and impaired fasting plasma glucose (FPG), and it is known to cause diabetes mellitus (DM) and other CVDs.

Obesity, which is defined as excessive accumulation of body fat mass (FM), increases the risk of MetS. In particular, abdominal obesity increases the risk of CVD by inducing insulin resistance, but femoral fat is related to buffering or improving the adverse effects of visceral fat cells rather than metabolic abnormalities.

Muscle is a major organ that participates in glucose metabolism. Sarcopenia, or low muscle mass, is associated with reduced physical activity and energy imbalance and causes MetS by reducing the utilization of glucose and free fatty acid. Sarcopenic obesity, which involves both obesity and low muscle mass, is known to lead to a higher risk of insulin resistance, DM, and MetS than that with obesity alone.

Studies related to increased FM or sarcopenic obesity mainly analyzed the relationship between total FM or total fat-free mass (FFM) and the risk of CVD. According to studies about regional FM, femoral fat was effective in improving glycemic control and lipid metabolism and lowering the risk of MetS and CVD. In elderly women, peripheral FM showed an independent anti-atherogenic effect, and central FM showed a positive correlation with arterial stiffness, whereas peripheral FM had a negative correlation. In regional FFM-related studies, one study of DM patients with obesity reported that relatively preserved leg muscle mass is associated with improved MetS parameters such as body mass index (BMI), waist-to-hip ratio, waist circumference (WC), and HDL-C. Another study of postmenopausal women described that FFM in the arm is associated with prevalence and severity of MetS.
As previously reported, the risk of CVD varies depending on the distribution of body composition. Therefore, it is important to understand the relationship between the regional FM or FFM distribution and the CVD-RF. In addition, there may be an imbalance in FM or FFM between the arms and legs or between the limbs and trunk, depending on factors such as sex, age, and physical activity. Therefore, it is necessary to consider these factors. However, there are only few studies on the relationship of regional FM or FFM ratios and the risk of CVD. This study aimed to analyze the association between FM or FFM ratios of the arms, legs, and trunk and the prevalence of CVD-RF including hypertension (HTN), DM, dyslipidemia (DL), and MetS using the Korea National Health and Nutrition Examination Survey (KNHANES) data.

Subjects and methods
Study population. This study obtained data from the 4th and 5th KNHANES (2008–2011), including whole-body dual-energy X-ray absorptiometry (DEXA). Of a total of 18,915 subjects, those aged ≥ 19 years were included in the analysis. We excluded those who had severe decline in kidney function (estimated glomerular filtration rate < 30 mL/min/1.73 m²), a history of cancer diagnosis, inappropriate fasting duration before examination (> 24 h or < 8 h), inappropriate nutritional intake (< 500 kcal/day or > 5000 kcal/day), inappropriate water intake per body weight (≥ 90 g/kg), and missing data in questionnaire records or unavailable test results (5883 persons). Finally, a total of 13,032 eligible participants (5425 men and 7607 women) were included in the analysis (Supplementary Fig. S1).

All procedures were approved by the ethics committee of the Korea Disease Control and Prevention Agency (Approval Number: 2011-02CON-06-C, 2010-02CON-21-C, 2009-01CON-03-2C, and 2008-04EXP-01-C), and the study was carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Signed informed consent was obtained from all KNHANES participants. The KNHANES data are publicly available.

Assessment of body compositions. Body compositions were measured using DEXA (Hologic Discovery, Hologic, USA)²⁰,²¹, including regional FM (both arms, both legs, and trunk), FFM (both arms, both legs, and trunk), and bone mineral contents (BMC) (both arms, both legs, right ribs, left ribs, thoracic and lumbar vertebrae, pelvis), to obtain data. Using these data, regional FM and FFM were calculated; FM of arms is the sum of FM in both arms, FM of legs is the sum of FM in both legs, FFM of arms is the value excluding both arm BMC from the sum of FFM in both arms; FFM of legs is the value excluding both leg BMC from the sum of FFM in both legs, and FFM of trunk is the value excluding the right ribs, left ribs, thoracic and lumbar vertebral, and pelvic BMC from the trunk FFM. Therefore, in this study, FFM is not exactly muscle mass and may include water and other organs as well as muscle mass. The arm-to-leg ratio or limbs-to-trunk ratio was calculated for FM and FFM, respectively, and grouped into quartiles from the lowest value (Q1) to the highest value (Q4).

Definitions of MetS. MetS was defined using two guidelines. First, based on the 2001 National Cholesterol Education Program (NCEP)/Adult Treatment Panel III (ATP III)⁴ and 2005 American Heart Association (AHA)/National Heart, Lung, and Blood Institute (NHLBI)²², MetS was defined when three or more of the following five criteria were satisfied: (1) WC ≥ 90 cm in men or ≥ 85 cm in women (based on abdominal obesity in Korean adults)²³; (2) TG ≥ 150 mg/dL or currently taking anti-dyslipidemic medications; (3) HDL-C < 40 mg/dL in men or < 50 mg/dL in women; (4) BP ≥ 130/85 mmHg or currently taking anti-hypertensive medications; (5) FPG ≥ 100 mg/dL or currently taking anti-hyperglycemic medications. Second, in accordance with the guideline of the 2006 International Diabetes Federation (IDF)⁴, MetS was defined when the abdominal obesity criterion (WC ≥ 90 cm in men or ≥ 85 cm in women) was met, and two or more of the following four criteria were satisfied: (1) TG ≥ 150 mg/dL or currently taking anti-dyslipidemic medications; (2) HDL-C < 40 mg/dL in men or < 50 mg/dL in women; (3) systolic BP ≥ 130 mmHg, diastolic BP ≥ 85 mmHg, or currently taking anti-hypertensive medications; (4) FPG ≥ 100 mg/dL or previous diagnosis of type 2 DM.

Measurement of covariates. The general characteristics of the participants by sex were analyzed using data on age, BMI, WC, FM, FFM, daily energy intake (total energy intake (TEI) and water intake per body weight (WIBW)), smoking (never, past, or current), alcohol drinking (< once or ≥ once/month), education (≤ elementary school, middle or high school, or ≥ college), average monthly household income (AMHI) (quartile), previous diagnosis of HTN by doctors, previous diagnosis of DM by doctors, previous diagnosis of DL by doctors, and survey year. Physical activity (PA) was described as Metabolic Equivalent (MET) or classified as low, moderate, or high PA level based on the data processing and analysis guidelines of the International Physical Activity Questionnaire (IPAQ)²³.

Statistical analysis. Statistical analysis was conducted using the STATA, ver. 14.0, statistical program, and statistical significance level was defined as p < 0.05. The sampling design for the KNHANES used two-stage stratified cluster sampling, not simple random sampling. For this reason, when analyzing data, weights were applied by reflecting the contents of this complex sampling design. Linear regression analyses and chi-square tests were used in comparative analysis of general characteristics by sex. The chi-square tests and the logistic regression analyses were performed to compare the prevalence of HTN, DM, DL and MetS according to the arm-to-leg ratio or the limbs-to-trunk ratio for FM and FFM, respectively. Odds ratio (OR) was calculated by adjusting for age, TEI, WIBW, smoking, alcohol drinking, PA, education, AMHI, and survey year. A linear regression was then conducted by regressing the OR to evaluate the trend (p for trend). In addition, linear regression analyses and chi-square tests were used in the analysis of FM or FFM ratio between body parts and the regional fat-to-fat-free mass ratio according to age and BMI.
Results

General characteristics of the study population by sex. The general characteristics of the study population by sex are shown in Table 1. Mean age of 13,032 participants was 44.22 years old, and 58.37% were women. The mean arm-to-leg FM ratio of all participants was 0.37, the mean limbs-to-trunk FM ratio was 0.87, the mean arm-to-leg FFM ratio was 0.32, and the mean limbs-to-trunk FFM ratio was 0.86. The arm-to-leg FM ratio (0.37 ± 0.002 vs. 0.36 ± 0.002), arm-to-leg FFM ratio (0.34 ± 0.001 vs. 0.29 ± 0.001), and limbs-to-trunk FFM ratio (0.91 ± 0.001 vs. 0.80 ± 0.001) were higher in men than in women, and the limbs-to-trunk FM ratio (0.75 ± 0.004 vs. 0.99 ± 0.005) was lower in men than in women; proportion of current smokers, alcohol drinkers (≥ once/month), participants with a high PA level, highly educated participants (college level or more), previous diagnosis of HTN or DM by doctors and MetS were also higher in men than in women. The proportion of previous diagnosis of DL by doctors was higher in women than in men.

Body composition distribution and prevalence of cardiovascular disease risk factors. A comparison of the prevalence of CVD-RF according to the distribution of body composition is shown in Table 2. In the arm-to-leg FM ratio, the prevalence of HTN, DM, DL, and MetS was the highest in Q4 in both men and women, and it increased as the ratio increased. In the limbs-to-trunk FM ratio, the prevalence of HTN, DM, DL, and MetS was the highest in Q1 in both men and women, and it increased as the ratio decreased. In the arm-to-leg FFM ratio, the prevalence of HTN, DM, DL, and MetS was the highest in Q4 in women, but DL was the highest in Q2 and MetS (IDF) was the highest in Q1 in men. In the limbs-to-trunk FFM ratio, the prevalence of HTN, DM, DL, and MetS was the highest in Q1 in both men and women, and it increased as the ratio decreased.

Arm-to-leg fat mass ratio and cardiovascular disease risk factors. The ORs for CVD-RF according to the quartile of the arm-to-leg FM ratio are shown in Table 3. The ORs for HTN (men: OR 2.16, 95% CI 1.62–2.88; women: OR 3.76, 95% CI 2.83–4.99), DM (men: OR 7.04, 95% CI 4.22–11.74; women: OR 10.57, 95% CI 6.38–11.95; women-IDF: OR 9.42, 95% CI 6.41–13.86) were significantly higher in Q4 than in Q1 in both men and women after adjustment for age, TEI, WIBW, smoking, alcohol drinking, PA, education, AMHI, and survey year. The ORs significantly decreased as the quartile increased from Q1 to Q4 (all p for trend <0.001).

Limbs-to-trunk fat mass ratio and cardiovascular disease risk factors. The ORs for CVD-RF according to the quartile of the limbs-to-trunk FM ratio are shown in Table 4. The ORs for HTN (men: OR 0.25, 95% CI 0.19–0.33; women: OR 0.14, 95% CI 0.10–0.21), DM (men: OR 0.12, 95% CI 0.07–0.21; women: OR 0.12, 95% CI 0.06–0.23), DL (men: OR 0.17, 95% CI 0.10–0.27; women: OR 0.20, 95% CI 0.13–0.31), and MetS (men-NCEP: OR 4.47, 95% CI 3.41–5.86; men-IDF: OR 3.63, 95% CI 2.61–5.05; women-NCEP: OR 8.73, 95% CI 6.38–11.95; women-IDF: OR 9.42, 95% CI 6.41–13.86) were significantly higher in Q4 than in Q1 in both men and women after adjustment for age, TEI, WIBW, smoking, alcohol drinking, PA, education, AMHI, and survey year. The ORs significantly increased as the quartile increased from Q1 to Q4 (all p for trend <0.001).

Arm-to-leg fat-free mass ratio and cardiovascular disease risk factors. The ORs for CVD-RF according to the quartile of the arm-to-leg FFM ratio are shown in Table 5. The ORs for MetS (men-NCEP: OR 0.75, 95% CI 0.59–0.94; men-IDF: OR 0.52, 95% CI 0.39–0.7; women-NCEP: OR 0.73, 95% CI 0.58–0.92; women-IDF: OR 0.61, 95% CI 0.47–0.79) were significantly lower in Q4 than in Q1 in both men and women after adjustment for age, TEI, WIBW, smoking, alcohol drinking, PA, education, AMHI, and survey year. The ORs significantly decreased as the quartile increased from Q1 to Q4 (all p for trend <0.001).

Limbs-to-trunk fat-free mass ratio and cardiovascular disease risk factors. The ORs for CVD-RF according to the quartile of the limbs-to-trunk FFM ratio are shown in Table 6. The ORs for HTN (men: OR 0.46, 95% CI 0.35–0.60; women: OR 0.55, 95% CI 0.44–0.69), DM (men: OR 0.19, 95% CI 0.11–0.31; women: OR 0.46, 95% CI 0.30–0.70), DL (men: OR 0.60, 95% CI 0.39–0.91; women: Crude OR 0.45, 95% CI 0.34–0.60), and MetS (men-NCEP: OR 0.39, 95% CI 0.31–0.50; men-IDF: OR 0.43, 95% CI 0.33–0.57; women-NCEP: OR 0.62, 95% CI 0.50–0.78; women-IDF: OR 0.62, 95% CI 0.49–0.80) were significantly lower in Q4 than in Q1 in both men and women after adjustment for age, TEI, WIBW, smoking, alcohol drinking, PA, education, AMHI, and survey year. The ORs significantly decreased as the quartile increased from Q1 to Q4 (all p for trend <0.05).

Fat mass or fat-free mass ratio between body parts according to age and body mass index. FM or FFM ratios between body parts according to age and BMI are shown in Supplementary Tables S1, S2. Compared to the group with BMI<25, the arm-to-leg FM ratio was relatively higher (p <0.001), and the arm-to-leg FFM ratio was also higher (p =0.004) in the group with BMI≥25. The limbs-to-trunk FM ratio was relatively lower (p <0.001) in the group with BMI≥25 than in the group with BMI<25.

As age increased, the arm-to-leg FM ratio increased (p <0.001), and the arm-to-leg FFM ratio also increased (p <0.001). The limbs-to-trunk FM ratio decreased (p <0.001), and the limbs-to-trunk FFM ratio also decreased (p <0.001) as age increased.

Regional fat-to-fat-free mass ratio according to age and body mass index. Regional fat-to-fat-free mass ratios according to age and BMI are shown in Supplementary Tables S3, S4. Compared to the group...
Table 1. General characteristics of the study participants. Data are presented as mean ± SE for continuous variables and numbers (%) for categorical variables. IPAQ, International Physical Activity Questionnaire; MetS, metabolic syndrome; WC, waist circumference; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure; FPG, fasting plasma glucose; NCEP, 2005 National Cholesterol Education Program Adult Treatment Panel III; IDF, 2006 International Diabetes Federation. *P value from linear regression analysis for continuous variables or χ² test for categorical variables, comparing differences between two groups. 

| Characteristics                              | Total (n = 13,032) | Male (n = 5425) | Female (n = 7607) | P value* |
|----------------------------------------------|--------------------|----------------|-------------------|----------|
| Age, years                                   | 44.22 ± 0.26       | 44.03 ± 0.33   | 44.40 ± 0.28      | 0.247    |
| Arm-to-leg fat mass ratio                    | 0.37 ± 0.001       | 0.37 ± 0.002   | 0.36 ± 0.002      | < 0.001  |
| Limbs-to-trunk fat mass ratio                | 0.87 ± 0.004       | 0.75 ± 0.004   | 0.99 ± 0.005      | < 0.001  |
| Arm-to-leg fat-free mass ratio               | 0.32 ± 0.001       | 0.34 ± 0.001   | 0.29 ± 0.001      | < 0.001  |
| Limbs-to-trunk fat-free mass ratio           | 0.86 ± 0.001       | 0.91 ± 0.001   | 0.80 ± 0.001      | < 0.001  |
| Waist circumference, cm                      | 80.67 ± 0.14       | 84.98 ± 0.18   | 77.62 ± 0.18      | < 0.001  |
| Body mass index, kg/m²                       | 23.59 ± 0.04       | 24.04 ± 0.06   | 23.19 ± 0.06      | < 0.001  |
| **Nutritional intake**                       |                    |                |                   |          |
| Total energy, kcal/day                       | 1988.60 ± 10.37    | 2331.98 ± 15.05| 1673.49 ± 9.70    | < 0.001  |
| Water intake/body weight, g/kg/day           | 15.73 ± 0.13       | 16.41 ± 0.17   | 15.11 ± 0.16      | < 0.001  |
| **Smoking**                                  |                    |                |                   | 0.001    |
| None                                         | 8176 (62.74)       | 1219 (22.47)   | 6957 (91.46)      |          |
| Past                                         | 2273 (17.44)       | 1989 (36.66)   | 284 (3.73)        |          |
| Current                                      | 2583 (19.82)       | 2217 (40.87)   | 366 (4.81)        |          |
| **Alcohol consumption**                      |                    |                |                   | < 0.001  |
| < 1 time/month                               | 5945 (45.62)       | 1377 (25.38)   | 4568 (60.05)      |          |
| ≥ 1 time/month                               | 7087 (54.38)       | 4048 (74.62)   | 3039 (39.95)      |          |
| **Physical activity (IPAQ)**                 |                    |                |                   | < 0.001  |
| Low                                          | 3990 (30.62)       | 1501 (27.67)   | 2489 (32.72)      |          |
| Moderate                                     | 5368 (41.19)       | 2101 (38.73)   | 3267 (42.95)      |          |
| High                                         | 3674 (28.19)       | 1823 (33.60)   | 1851 (24.33)      |          |
| **Education**                                |                    |                |                   | < 0.001  |
| ≤ Elementary school                          | 3009 (23.09)       | 860 (15.85)    | 2149 (28.25)      |          |
| Middle or high school                        | 5349 (41.05)       | 2278 (41.99)   | 3071 (40.37)      |          |
| ≥ College                                    | 4674 (35.87)       | 2287 (42.16)   | 2387 (31.38)      |          |
| **Income**                                   |                    |                |                   | 0.560    |
| Q1                                           | 3121 (23.95)       | 1277 (23.54)   | 1844 (24.24)      |          |
| Q2                                           | 3367 (25.84)       | 1413 (26.05)   | 1954 (25.69)      |          |
| Q3                                           | 3313 (25.42)       | 1363 (25.12)   | 1950 (25.63)      |          |
| Q4                                           | 3231 (24.79)       | 1372 (25.29)   | 1859 (24.44)      |          |
| **Survey year**                              |                    |                |                   | 0.050    |
| 2008                                         | 2400 (18.42)       | 940 (17.33)    | 1460 (19.19)      |          |
| 2009                                         | 5021 (38.53)       | 2127 (39.21)   | 2894 (38.04)      |          |
| 2010                                         | 3976 (30.51)       | 1681 (30.99)   | 2295 (30.17)      |          |
| 2011                                         | 1635 (12.55)       | 677 (12.48)    | 958 (12.59)       |          |
| **Comorbidity**                              |                    |                |                   |          |
| Hypertension                                 | 2648 (20.32)       | 1209 (22.29)   | 1439 (18.92)      | < 0.001  |
| Diabetes                                     | 940 (7.21)         | 457 (8.42)     | 483 (6.35)        | < 0.001  |
| Dyslipidemia                                 | 1178 (9.04)        | 445 (8.20)     | 733 (9.64)        | 0.005    |
| **MetS component**                           |                    |                |                   |          |
| WC ≥ 90 cm                                   | 3330 (25.55)       | 1428 (26.32)   | 1902 (25.00)      | 0.089    |
| TG ≥ 150 mg/dL, or drug treatment for dyslipidemia | 3559 (27.31)       | 1994 (36.76)   | 1565 (20.57)      | < 0.001  |
| HDL-C < 40 mg/dL                             | 5766 (44.24)       | 1830 (33.73)   | 3936 (51.74)      | < 0.001  |
| BP ≥ 130/85 mmHg or drug treatment for elevated BP | 3624 (27.81)       | 1807 (33.31)   | 1817 (23.89)      | < 0.001  |
| FPG ≥ 100 mg/dL, or drug treatment for elevated FPG | 3447 (26.45)       | 1798 (33.14)   | 1649 (21.68)      | < 0.001  |
| MetS (NCEP)                                  | 3070 (23.56)       | 1435 (26.45)   | 1635 (21.49)      | < 0.001  |
| MetS (IDF)                                   | 2071 (15.89)       | 915 (16.87)    | 1156 (15.20)      | 0.010    |
|                | Male Arm-to-leg fat mass ratio | Female Arm-to-leg fat mass ratio | Male Limbs-to-trunk fat mass ratio | Female Limbs-to-trunk fat mass ratio | Male Arm-to-leg fat-free mass ratio | Female Arm-to-leg fat-free mass ratio |
|----------------|-------------------------------|---------------------------------|-----------------------------------|-------------------------------------|-----------------------------------|---------------------------------------|
|                | Q1 (n = 1322)                 | Q2 (n = 1358)                   | Q3 (n = 1370)                     | Q4 (n = 1375)                       | Q1 (n = 1322)                     | Q2 (n = 1358)                         |
|                  |                               |                                 |                                   |                                     |                                   |                                       |
| Hypertension    | 132 (9.98)                    | 278 (20.47)                     | 374 (27.30)                       | 425 (30.91)                         | 94 (4.89)                         | 230 (12.05)                           |
| Diabetes        | 26 (1.97)                     | 82 (6.04)                       | 123 (8.98)                        | 226 (16.44)                         | 14 (0.73)                         | 44 (2.30)                             |
| Dyslipidemia    | 46 (3.48)                     | 100 (7.36)                      | 132 (9.64)                        | 167 (12.15)                         | 36 (1.87)                         | 132 (6.91)                            |
| MetS (NCEP)     | 138 (10.44)                   | 321 (23.64)                     | 442 (32.26)                       | 534 (38.84)                         | 82 (4.27)                         | 224 (11.73)                           |
| MetS (IDF)      | 92 (6.96)                     | 207 (15.24)                     | 294 (21.46)                       | 322 (23.42)                         | 47 (2.45)                         | 144 (7.54)                            |
|                |                               |                                 |                                   |                                     |                                   |                                       |
| Male Limbs-to-trunk fat mass ratio | Q1 (n = 1322)                 | Q2 (n = 1358)                   | Q3 (n = 1370)                     | Q4 (n = 1375)                       | Q1 (n = 1322)                     | Q2 (n = 1358)                         |
|                  |                               |                                 |                                   |                                     |                                   |                                       |
| Hypertension    | 514 (37.82)                   | 365 (26.35)                     | 211 (15.47)                       | 119 (9.04)                          | 747 (40.44)                       | 461 (24.80)                           |
| Diabetes        | 245 (18.03)                   | 126 (9.10)                      | 60 (4.40)                         | 26 (1.97)                           | 293 (15.86)                       | 127 (6.83)                            |
| Dyslipidemia    | 204 (15.01)                   | 138 (9.96)                      | 73 (5.35)                         | 30 (2.28)                           | 358 (19.38)                       | 220 (11.83)                           |
| MetS (NCEP)     | 660 (48.57)                   | 457 (33.00)                     | 257 (18.84)                       | 61 (4.63)                           | 909 (49.21)                       | 531 (28.56)                           |
| MetS (IDF)      | 447 (32.89)                   | 294 (21.23)                     | 148 (10.85)                       | 61 (4.63)                           | 668 (36.17)                       | 366 (19.69)                           |
|                |                               |                                 |                                   |                                     |                                   |                                       |
| Male Arm-to-leg fat-free mass ratio | Q1 (n = 1322)                 | Q2 (n = 1358)                   | Q3 (n = 1370)                     | Q4 (n = 1375)                       | Q1 (n = 1322)                     | Q2 (n = 1358)                         |
|                  |                               |                                 |                                   |                                     |                                   |                                       |
| Hypertension    | 289 (21.11)                   | 315 (23.01)                     | 322 (23.23)                       | 283 (21.75)                         | 188 (9.38)                        | 291 (15.09)                           |
| Diabetes        | 125 (9.13)                    | 122 (8.91)                      | 112 (8.08)                        | 98 (7.53)                           | 65 (3.24)                         | 102 (5.29)                            |
| Dyslipidemia    | 116 (8.47)                    | 135 (9.86)                      | 118 (8.51)                        | 76 (5.84)                           | 136 (6.78)                        | 180 (9.33)                            |
| MetS (NCEP)     | 370 (27.03)                   | 380 (27.76)                     | 377 (27.20)                       | 308 (23.67)                         | 276 (10.16)                       | 245 (17.90)                           |
| MetS (IDF)      | 276 (20.16)                   | 286 (16.45)                     | 228 (16.45)                       | 166 (12.76)                         | 668 (36.17)                       | 366 (19.69)                           |
|                |                               |                                 |                                   |                                     |                                   |                                       |
| Male Limbs-to-trunk fat-free mass ratio | Q1 (n = 1322)                 | Q2 (n = 1358)                   | Q3 (n = 1370)                     | Q4 (n = 1375)                       | Q1 (n = 1322)                     | Q2 (n = 1358)                         |
|                  |                               |                                 |                                   |                                     |                                   |                                       |
| Hypertension    | 504 (37.89)                   | 317 (23.14)                     | 250 (18.23)                       | 138 (10.19)                         | 188 (9.38)                        | 291 (15.09)                           |
| Diabetes        | 250 (18.00)                   | 122 (8.91)                      | 60 (4.38)                         | 25 (1.85)                           | 65 (3.24)                         | 102 (5.29)                            |
| Dyslipidemia    | 162 (12.18)                   | 129 (9.42)                      | 91 (6.64)                         | 63 (4.65)                           | 136 (6.78)                        | 180 (9.33)                            |
| MetS (NCEP)     | 518 (38.95)                   | 378 (27.59)                     | 318 (23.19)                       | 221 (16.32)                         | 276 (10.16)                       | 286 (14.83)                           |
| MetS (IDF)      | 340 (25.56)                   | 223 (16.28)                     | 197 (14.37)                       | 155 (11.45)                         | 210 (10.47)                       | 286 (14.83)                           |

Table 2. Prevalence of cardiovascular disease risk factors according to body composition ratio quartile. MetS, metabolic syndrome; NCEP, 2005 National Cholesterol Education Program Adult Treatment Panel III; IDF, 2006 International Diabetes Federation. Data are presented as numbers (%). *P* value from $\chi^2$ test for categorical variables, comparing differences among four groups.
Table 3. Odds ratios for cardiovascular disease risk factors according to arm-to-leg fat mass ratio quartile. Data are presented as odds ratio (95% confidence interval). MetS, metabolic syndrome; NCEP, 2005 National Cholesterol Education Program Adult Treatment Panel III; IDF, 2006 International Diabetes Federation.

*a Multivariable model adjusted for age, energy intake, water intake per body weight, smoking, alcohol drinking, physical activity, education, income, and survey year. b Test for linear trend across quartile of arm-to-leg fat mass ratio.

|        | Male | Arm-to-leg fat mass ratio quartile | Crude | Age-adjusted | Multivariable* |
|--------|------|----------------------------------|-------|--------------|---------------|
|        |      | Q1 | Reference | Reference | Reference | Reference |
| Hypertension |      | Q2 | 2.29 (1.74–3.01) | 1.57 (1.17–2.1) | 1.58 (1.17–2.12) |  
|        |      | Q3 | 3.65 (2.83–4.72) | 2.07 (1.56–2.74) | 2.06 (1.55–2.73) |  
|        |      | Q4 | 4.57 (3.54–5.91) | 2.15 (1.62–2.85) | 2.16 (1.62–2.88) |  
| p for trendb |      | < 0.001 | < 0.001 | < 0.001 |  
|        |      | Q1 | Reference | Reference | Reference | Reference |
| Diabetes |      | Q2 | 3.44 (2.04–5.78) | 2.4 (1.41–4.1) | 2.48 (1.46–4.19) |  
|        |      | Q3 | 5.46 (3.3–9.05) | 3.24 (1.93–5.43) | 3.4 (2.03–5.68) |  
|        |      | Q4 | 12.73 (7.69–21.07) | 6.66 (3.97–11.18) | 7.04 (4.22–11.74) |  
| p for trendb |      | < 0.001 | < 0.001 | < 0.001 |  
|        |      | Q1 | Reference | Reference | Reference | Reference |
| Dyslipidemia |      | Q2 | 2.17 (1.45–3.26) | 1.75 (1.15–2.66) | 1.73 (1.13–2.64) |  
|        |      | Q3 | 3.62 (2.41–5.44) | 2.59 (1.69–3.96) | 2.5 (1.63–3.82) |  
|        |      | Q4 | 4.8 (3.26–7.07) | 3.12 (2.06–4.71) | 3.09 (2.05–4.68) |  
| p for trendb |      | < 0.001 | < 0.001 | < 0.001 |  
|        |      | Q1 | Reference | Reference | Reference | Reference |
| MetS (NCEP) |      | Q2 | 2.73 (2.1–3.54) | 2.33 (1.79–3.04) | 2.35 (1.8–3.07) |  
|        |      | Q3 | 4.8 (3.67–6.28) | 3.74 (2.83–4.93) | 3.65 (2.75–4.84) |  
|        |      | Q4 | 6.22 (4.82–8.03) | 4.49 (3.45–5.86) | 4.47 (3.41–5.86) |  
| p for trendb |      | < 0.001 | < 0.001 | < 0.001 |  
|        |      | Q1 | Reference | Reference | Reference | Reference |
| MetS (IDF) |      | Q2 | 2.49 (1.82–3.42) | 2.2 (1.59–3.04) | 2.24 (1.62–3.09) |  
|        |      | Q3 | 4.38 (3.18–6.03) | 3.58 (2.57–5) | 3.51 (2.51–4.91) |  
|        |      | Q4 | 4.71 (3.44–6.43) | 3.62 (2.61–5.03) | 3.63 (2.61–5.05) |  
| p for trendb |      | < 0.001 | < 0.001 | < 0.001 |  
|        |      | Q1 | Reference | Reference | Reference | Reference |
| Female |      | Q2 | 3.01 (2.24–4.05) | 1.79 (1.28–2.5) | 1.67 (1.19–2.33) |  
| Hypertension |      | Q3 | 6.32 (4.82–8.28) | 2.61 (1.93–3.52) | 2.38 (1.76–3.22) |  
|        |      | Q4 | 14.33 (11.03–18.6) | 4.13 (3.09–5.5) | 3.76 (2.83–4.99) |  
| p for trendb |      | < 0.001 | < 0.001 | < 0.001 |  
|        |      | Q1 | Reference | Reference | Reference | Reference |
| Diabetes |      | Q2 | 3.1 (1.65–6.62) | 2.22 (1.12–4.39) | 2.2 (1.11–4.36) |  
|        |      | Q3 | 8.2 (4.32–15.56) | 4.11 (2.19–7.71) | 3.98 (2.12–7.49) |  
|        |      | Q4 | 28.14 (15.34–51.63) | 10.96 (6.02–19.95) | 10.57 (5.8–19.26) |  
| p for trendb |      | < 0.001 | < 0.001 | < 0.001 |  
|        |      | Q1 | Reference | Reference | Reference | Reference |
| Dyslipidemia |      | Q2 | 3.76 (2.44–5.8) | 2.7 (1.74–4.2) | 2.49 (1.59–3.9) |  
|        |      | Q3 | 7.43 (4.85–11.38) | 4.16 (2.67–6.48) | 3.73 (2.37–5.86) |  
|        |      | Q4 | 15.83 (10.18–24.6) | 6.91 (4.3–11.1) | 6.47 (3.99–10.5) |  
| p for trendb |      | < 0.001 | < 0.001 | < 0.001 |  
|        |      | Q1 | Reference | Reference | Reference | Reference |
| MetS (NCEP) |      | Q2 | 3.23 (2.38–4.39) | 2.29 (1.68–3.14) | 2.26 (1.64–3.11) |  
|        |      | Q3 | 8.33 (6.22–11.16) | 4.71 (3.49–6.36) | 4.4 (3.25–5.96) |  
|        |      | Q4 | 21.05 (15.68–28.26) | 9.25 (6.79–12.59) | 8.73 (6.38–11.95) |  
| p for trendb |      | < 0.001 | < 0.001 | < 0.001 |  
|        |      | Q1 | Reference | Reference | Reference | Reference |
| MetS (IDF) |      | Q2 | 3.1 (2.07–4.64) | 2.34 (1.56–3.51) | 2.28 (1.51–3.44) |  
|        |      | Q3 | 8.98 (6.11–13.2) | 5.57 (3.77–8.24) | 5.12 (3.46–7.59) |  
|        |      | Q4 | 20.38 (14.04–29.58) | 10.19 (6.94–14.96) | 9.42 (6.41–13.86) |  
| p for trendb |      | < 0.001 | < 0.001 | < 0.001 |  

| Male | Limbs-to-trunk fat mass ratio quartile | Crude | Age-adjusted | Multivariable* |
|------|--------------------------------------|-------|--------------|---------------|
|      |                                      |       |              |               |
| Hypertension |                                |       |              |               |
| Q1   | Reference                            | Reference | Reference |
| Q2   | 0.56 (0.46–0.68)                     | 0.7 (0.56–0.86) | 0.69 (0.56–0.86) |
| Q3   | 0.26 (0.21–0.32)                     | 0.4 (0.32–0.51) | 0.41 (0.32–0.52) |
| Q4   | 0.12 (0.09–0.15)                     | 0.24 (0.19–0.32) | 0.25 (0.19–0.33) |
| p for trend** | < 0.001                             | < 0.001   | < 0.001      |
| Diabetes |                                |       |              |               |
| Q1   | Reference                            | Reference | Reference |
| Q2   | 0.43 (0.32–0.57)                     | 0.51 (0.38–0.69) | 0.49 (0.37–0.66) |
| Q3   | 0.26 (0.14–0.28)                     | 0.3 (0.21–0.42) | 0.28 (0.19–0.4) |
| Q4   | 0.07 (0.04–0.12)                     | 0.14 (0.08–0.23) | 0.12 (0.07–0.21) |
| p for trend** | < 0.001                             | < 0.001   | < 0.001      |
| Dyslipidemia |                               |       |              |               |
| Q1   | Reference                            | Reference | Reference |
| Q2   | 0.58 (0.45–0.76)                     | 0.65 (0.49–0.86) | 0.67 (0.51–0.88) |
| Q3   | 0.26 (0.19–0.37)                     | 0.34 (0.24–0.48) | 0.36 (0.25–0.51) |
| Q4   | 0.1 (0.06–0.16)                      | 0.15 (0.09–0.24) | 0.17 (0.1–0.27) |
| p for trend** | < 0.001                             | < 0.001   | < 0.001      |
| MetS (NCEP) |                              |       |              |               |
| Q1   | Reference                            | Reference | Reference |
| Q2   | 0.49 (0.41–0.6)                      | 0.53 (0.43–0.64) | 0.52 (0.43–0.63) |
| Q3   | 0.22 (0.17–0.27)                     | 0.25 (0.2–0.31) | 0.25 (0.2–0.31) |
| Q4   | 0.04 (0.03–0.06)                     | 0.06 (0.04–0.08) | 0.06 (0.04–0.08) |
| p for trend** | < 0.001                             | < 0.001   | < 0.001      |
| MetS (IDF) |                             |       |              |               |
| Q1   | Reference                            | Reference | Reference |
| Q2   | 0.51 (0.41–0.63)                     | 0.52 (0.42–0.65) | 0.52 (0.41–0.65) |
| Q3   | 0.22 (0.17–0.28)                     | 0.23 (0.18–0.3) | 0.23 (0.18–0.3) |
| Q4   | 0.04 (0.02–0.06)                     | 0.04 (0.02–0.07) | 0.04 (0.02–0.07) |
| p for trend** | < 0.001                             | < 0.001   | < 0.001      |
| Female | Limbs-to-trunk fat mass ratio quartile | Crude | Age-adjusted | Multivariable* |
|       |                                      |       |              |               |
| Hypertension |                                |       |              |               |
| Q1   | Reference                            | Reference | Reference |
| Q2   | 0.48 (0.41–0.56)                     | 0.66 (0.55–0.8) | 0.66 (0.55–0.79) |
| Q3   | 0.15 (0.12–0.18)                     | 0.33 (0.26–0.43) | 0.34 (0.26–0.43) |
| Q4   | 0.03 (0.02–0.04)                     | 0.13 (0.09–0.19) | 0.14 (0.1–0.21) |
| p for trend** | < 0.001                             | < 0.001   | < 0.001      |
| Diabetes |                                |       |              |               |
| Q1   | Reference                            | Reference | Reference |
| Q2   | 0.4 (0.31–0.52)                      | 0.51 (0.39–0.66) | 0.49 (0.38–0.64) |
| Q3   | 0.13 (0.09–0.19)                     | 0.24 (0.16–0.36) | 0.23 (0.16–0.35) |
| Q4   | 0.04 (0.02–0.07)                     | 0.12 (0.06–0.22) | 0.12 (0.06–0.23) |
| p for trend** | < 0.001                             | < 0.001   | < 0.001      |
| Dyslipidemia |                               |       |              |               |
| Q1   | Reference                            | Reference | Reference |
| Q2   | 0.57 (0.45–0.72)                     | 0.71 (0.55–0.91) | 0.72 (0.57–0.93) |
| Q3   | 0.22 (0.16–0.28)                     | 0.37 (0.28–0.5) | 0.38 (0.29–0.51) |
| Q4   | 0.07 (0.05–0.1)                      | 0.17 (0.11–0.27) | 0.2 (0.13–0.31) |
| p for trend** | < 0.001                             | < 0.001   | < 0.001      |
| MetS (NCEP) |                              |       |              |               |
| Q1   | Reference                            | Reference | Reference |
| Q2   | 0.42 (0.36–0.49)                     | 0.5 (0.42–0.58) | 0.49 (0.41–0.58) |
| Q3   | 0.09 (0.07–0.11)                     | 0.14 (0.11–0.17) | 0.14 (0.11–0.18) |
| Q4   | 0.01 (0.01–0.02)                     | 0.02 (0.01–0.04) | 0.02 (0.01–0.04) |
| p for trend** | < 0.001                             | < 0.001   | < 0.001      |
| MetS (IDF) |                             |       |              |               |
| Q1   | Reference                            | Reference | Reference |
| Q2   | 0.45 (0.38–0.54)                     | 0.52 (0.44–0.63) | 0.52 (0.43–0.62) |
| Q3   | 0.1 (0.08–0.14)                      | 0.14 (0.11–0.19) | 0.15 (0.11–0.2) |
| Q4   | 0.01 (0–0.02)                        | 0.01 (0.01–0.03) | 0.02 (0.01–0.03) |
| p for trend** | < 0.001                             | < 0.001   | < 0.001      |

Table 4. Odds ratios for cardiovascular disease risk factors according to limbs-to-trunk fat mass ratio quartile. Data are presented as odds ratio (95% confidence interval). MetS, metabolic syndrome; NCEP, 2005 National Cholesterol Education Program Adult Treatment Panel III; IDF, 2006 International Diabetes Federation. 

*Multivariable model adjusted for age, energy intake, water intake per body weight, smoking, alcohol drinking, physical activity, education, income, and survey year.

**Test for linear trend across quartile of limbs-to-trunk fat mass ratio.
Table 5. Odds ratios for cardiovascular disease risk factors according to arm-to-leg fat-free mass ratio quartile. Data are presented as odds ratio (95% confidence interval). MetS, metabolic syndrome; NCEP, 2005 National Cholesterol Education Program Adult Treatment Panel III; IDF, 2006 International Diabetes Federation. aMultivariable model adjusted for age, energy intake, water intake per body weight, smoking, alcohol drinking, physical activity, education, income, and survey year. bTest for linear trend across quartile of arm-to-leg fat-free mass ratio.

|                          | Male Arm-to-leg fat-free mass ratio quartile | Crude | Age-adjusted | Multivariable* |
|--------------------------|--------------------------------------------|-------|--------------|----------------|
| **Hypertension**         |                                            |       |              |                |
| Q1                       | Reference                                  |       | Reference    | Reference      |
| Q2                       | 1.26 (1.01–1.57)                           | 1.02  | (0.8–1.3)    | 1.01 (0.79–1.29) |
| Q3                       | 1.32 (1.06–1.64)                           | 1.05  | (0.82–1.36)  | 1.06 (0.81–1.39) |
| Q4                       | 1.19 (0.93–1.51)                           | 0.91  | (0.7–1.18)   | 0.93 (0.71–1.22) |
| p for trendb             | 0.123                                      | 0.537 |              | 0.710          |
| **Diabetes**             |                                            |       |              |                |
| Q1                       | Reference                                  |       | Reference    | Reference      |
| Q2                       | 1.06 (0.78–1.44)                           | 0.87  | (0.64–1.18)  | 0.85 (0.62–1.17) |
| Q3                       | 1.13 (0.82–1.55)                           | 0.93  | (0.67–1.29)  | 0.91 (0.66–1.25) |
| Q4                       | 1.11 (0.79–1.54)                           | 0.9   | (0.65–1.27)  | 0.84 (0.59–1.21) |
| p for trendb             | 0.480                                      | 0.676 |              | 0.447          |
| **Dyslipidemia**         |                                            |       |              |                |
| Q1                       | Reference                                  |       | Reference    | Reference      |
| Q2                       | 1.35 (0.98–1.85)                           | 1.18  | (0.85–1.64)  | 1.2 (0.86–1.67) |
| Q3                       | 1.22 (0.88–1.69)                           | 1.06  | (0.75–1.48)  | 1.11 (0.79–1.57) |
| Q4                       | 0.81 (0.57–1.14)                           | 0.68  | (0.47–0.97)  | 0.72 (0.49–1.04) |
| p for trendb             | 0.230                                      | 0.024 |              | 0.085          |
| **MetS (NCEP)**          |                                            |       |              |                |
| Q1                       | Reference                                  |       | Reference    | Reference      |
| Q2                       | 1.02 (0.83–1.25)                           | 0.89  | (0.72–1.09)  | 0.85 (0.69–1.05) |
| Q3                       | 0.98 (0.79–1.21)                           | 0.84  | (0.67–1.04)  | 0.8 (0.65–1)   |
| Q4                       | 0.96 (0.77–1.2)                            | 0.8   | (0.64–0.99)  | 0.75 (0.59–0.94) |
| p for trendb             | 0.679                                      | 0.033 |              | 0.011          |
| **MetS (IDF)**           |                                            |       |              |                |
| Q1                       | Reference                                  |       | Reference    | Reference      |
| Q2                       | 0.87 (0.69–1.1)                            | 0.78  | (0.61–0.98)  | 0.74 (0.58–0.94) |
| Q3                       | 0.77 (0.61–0.98)                           | 0.68  | (0.54–0.86)  | 0.66 (0.51–0.84) |
| Q4                       | 0.65 (0.5–0.86)                            | 0.55  | (0.42–0.73)  | 0.52 (0.39–0.7) |
| p for trendb             | 0.001                                      | < 0.001|              | < 0.001        |
| **Female Arm-to-leg fat-free mass ratio quartile** | Crude | Age-adjusted | Multivariable* |
| **Hypertension**         |                                            |       |              |                |
| Q1                       | Reference                                  |       | Reference    | Reference      |
| Q2                       | 1.83 (1.44–2.33)                           | 1.02  | (0.78–1.34)  | 0.97 (0.74–1.28) |
| Q3                       | 3.14 (2.44–4.05)                           | 1.29  | (0.98–1.71)  | 1.17 (0.88–1.55) |
| Q4                       | 5.02 (3.95–6.38)                           | 1.16  | (0.88–1.54)  | 1.03 (0.78–1.36) |
| p for trendb             | < 0.001                                   | 0.140 |              | 0.611          |
| **Diabetes**             |                                            |       |              |                |
| Q1                       | Reference                                  |       | Reference    | Reference      |
| Q2                       | 1.94 (1.33–2.84)                           | 1.25  | (0.84–1.85)  | 1.16 (0.78–1.73) |
| Q3                       | 2.79 (1.91–4.06)                           | 1.37  | (0.93–2.01)  | 1.2 (0.81–1.77) |
| Q4                       | 3.77 (2.67–5.32)                           | 1.2   | (0.81–1.78)  | 1.01 (0.68–1.5) |
| p for trendb             | < 0.001                                   | 0.434 |              | 0.852          |
| **Dyslipidemia**         |                                            |       |              |                |
| Q1                       | Reference                                  |       | Reference    | Reference      |
| Q2                       | 1.66 (1.27–2.17)                           | 1.12  | (0.85–1.49)  | 1.07 (0.81–1.42) |
| Q3                       | 1.75 (1.31–2.35)                           | 0.92  | (0.67–1.26)  | 0.86 (0.63–1.17) |
| Q4                       | 2.77 (2.11–3.63)                           | 0.99  | (0.72–1.37)  | 0.96 (0.71–1.31) |
| p for trendb             | < 0.001                                   | 0.639 |              | 0.503          |
| **MetS (NCEP)**          |                                            |       |              |                |
| Q1                       | Reference                                  |       | Reference    | Reference      |
| Q2                       | 1.61 (1.32–1.97)                           | 1.06  | (0.84–1.33)  | 1 (0.8–1.26)   |
| Q3                       | 2 (1.64–2.44)                              | 1.0   | (0.81–1.24)  | 0.9 (0.73–1.12) |
| Q4                       | 2.64 (2.16–3.23)                           | 0.84  | (0.67–1.06)  | 0.73 (0.58–0.92) |
| p for trendb             | < 0.001                                   | 0.086 |              | 0.003          |
| **MetS (IDF)**           |                                            |       |              |                |
| Q1                       | Reference                                  |       | Reference    | Reference      |
| Q2                       | 1.48 (1.18–1.85)                           | 1.01  | (0.79–1.28)  | 0.94 (0.74–1.2) |
| Q3                       | 1.82 (1.45–2.27)                           | 0.98  | (0.78–1.23)  | 0.84 (0.66–1.06) |
| Q4                       | 2.09 (1.65–2.65)                           | 0.75  | (0.59–0.97)  | 0.61 (0.47–0.79) |
| p for trendb             | < 0.001                                   | 0.020 |              | < 0.001        |
| Male | Limbs-to-trunk fat-free mass ratio quartile | Crude                   | Age-adjusted              | Multivariablea |
|------|------------------------------------------|-------------------------|---------------------------|----------------|
|      |                                          | Crude                   | Age-adjusted              |                |
|      |                                          | p for trendb             |                           |                |
| Hypertension | Q1 | Reference                      | Reference                  | Reference |
|          | Q2 | 0.48 (0.39–0.59)               | 0.67 (0.54–0.84)           | 0.66 (0.52–0.82) |
|          | Q3 | 0.34 (0.28–0.42)               | 0.64 (0.51–0.81)           | 0.63 (0.5–0.81) |
|          | Q4 | 0.17 (0.14–0.22)               | 0.48 (0.37–0.63)           | 0.46 (0.35–0.6) |
| p for trendb |    | <0.001                          | <0.001                     | <0.001        |
| Diabetes | Q1 | Reference                      | Reference                  | Reference |
|          | Q2 | 0.47 (0.35–0.63)               | 0.63 (0.46–0.86)           | 0.66 (0.48–0.9) |
|          | Q3 | 0.19 (0.13–0.27)               | 0.32 (0.22–0.45)           | 0.32 (0.23–0.46) |
|          | Q4 | 0.08 (0.05–0.12)               | 0.18 (0.11–0.3)            | 0.19 (0.11–0.31) |
| p for trendb |    | <0.001                          | <0.001                     | <0.001        |
| Dyslipidemia | Q1 | Reference                      | Reference                  | Reference |
|          | Q2 | 0.69 (0.51–0.92)               | 0.85 (0.53–1.15)           | 0.85 (0.63–1.16) |
|          | Q3 | 0.45 (0.33–0.62)               | 0.65 (0.46–0.93)           | 0.67 (0.47–0.95) |
|          | Q4 | 0.32 (0.22–0.47)               | 0.58 (0.38–0.89)           | 0.6 (0.39–0.91) |
| p for trendb |    | <0.001                          | <0.001                     | <0.001        |
| MetS (NCEP) | Q1 | Reference                      | Reference                  | Reference |
|          | Q2 | 0.57 (0.47–0.7)                | 0.67 (0.55–0.83)           | 0.67 (0.54–0.82) |
|          | Q3 | 0.43 (0.35–0.54)               | 0.58 (0.46–0.72)           | 0.58 (0.46–0.72) |
|          | Q4 | 0.25 (0.2–0.31)                | 0.39 (0.31–0.5)            | 0.39 (0.31–0.5) |
| p for trendb |    | <0.001                          | <0.001                     | <0.001        |
| MetS (IDF) | Q1 | Reference                      | Reference                  | Reference |
|          | Q2 | 0.52 (0.42–0.66)               | 0.6 (0.47–0.75)            | 0.58 (0.46–0.74) |
|          | Q3 | 0.43 (0.34–0.54)               | 0.54 (0.42–0.68)           | 0.53 (0.42–0.68) |
|          | Q4 | 0.31 (0.24–0.4)                | 0.44 (0.34–0.58)           | 0.43 (0.33–0.57) |
| p for trendb |    | <0.001                          | <0.001                     | <0.001        |
| Female | Limbs-to-trunk fat-free mass ratio quartile | Crude                   | Age-adjusted              | Multivariablea |
|        |                                          | Crude                   | Age-adjusted              |                |
|        |                                          | p for trendb             |                           |                |
| Hypertension | Q1 | Reference                      | Reference                  | Reference |
|          | Q2 | 0.64 (0.53–0.78)               | 0.79 (0.64–0.99)           | 0.78 (0.63–0.98) |
|          | Q3 | 0.5 (0.41–0.6)                 | 0.81 (0.65–1.02)           | 0.81 (0.64–1.01) |
|          | Q4 | 0.28 (0.22–0.35)               | 0.55 (0.43–0.69)           | 0.55 (0.44–0.69) |
| p for trendb |    | <0.001                          | <0.001                     | <0.001        |
| Diabetes | Q1 | Reference                      | Reference                  | Reference |
|          | Q2 | 0.67 (0.5–0.89)                | 0.82 (0.61–1.12)           | 0.82 (0.61–1.12) |
|          | Q3 | 0.32 (0.23–0.44)               | 0.47 (0.34–0.66)           | 0.47 (0.34–0.66) |
|          | Q4 | 0.25 (0.17–0.37)               | 0.46 (0.31–0.68)           | 0.46 (0.3–0.7) |
| p for trendb |    | <0.001                          | <0.001                     | <0.001        |
| Dyslipidemia | Q1 | Reference                      | Reference                  | Reference |
|          | Q2 | 0.81 (0.64–1.03)               | 0.99 (0.76–1.28)           | 0.96 (0.74–1.24) |
|          | Q3 | 0.64 (0.5–0.83)                | 0.94 (0.72–1.24)           | 0.94 (0.71–1.23) |
|          | Q4 | 0.45 (0.34–0.6)                | 0.79 (0.58–1.08)           | 0.8 (0.58–1.1) |
| p for trendb |    | <0.001                          | <0.001                     | <0.001        |
| MetS (NCEP) | Q1 | Reference                      | Reference                  | Reference |
|          | Q2 | 0.57 (0.47–0.68)               | 0.65 (0.53–0.79)           | 0.64 (0.52–0.79) |
|          | Q3 | 0.48 (0.41–0.57)               | 0.69 (0.57–0.83)           | 0.69 (0.57–0.83) |
|          | Q4 | 0.36 (0.3–0.44)                | 0.63 (0.51–0.79)           | 0.62 (0.5–0.78) |
| p for trendb |    | <0.001                          | <0.001                     | <0.001        |
| MetS (IDF) | Q1 | Reference                      | Reference                  | Reference |
|          | Q2 | 0.56 (0.46–0.69)               | 0.65 (0.53–0.78)           | 0.64 (0.51–0.79) |
|          | Q3 | 0.51 (0.42–0.61)               | 0.7 (0.58–0.86)            | 0.7 (0.57–0.87) |
|          | Q4 | 0.38 (0.3–0.48)                | 0.63 (0.49–0.8)            | 0.62 (0.49–0.8) |
| p for trendb |    | <0.001                          | <0.001                     | <0.001        |

Table 6. Odds ratios for cardiovascular disease risk factors according to limbs-to-trunk fat-free mass ratio quartile. Data are presented as odds ratio (95% confidence interval). MetS, metabolic syndrome; NCEP, 2005 National Cholesterol Education Program Adult Treatment Panel III; IDF, 2006 International Diabetes Federation. *Multivariable model adjusted for age, energy intake, water intake per body weight, smoking, alcohol drinking, physical activity, education, income, and survey year. bTest for linear trend across quartile of limbs-to-trunk fat-free mass ratio.
with BMI < 25, the fat-to-fat-free mass ratio was higher in the arms, legs, and trunk in the group with BMI ≥ 25 (all p < 0.001). In other words, as BMI increased, FM increased at a higher rate than FFM in any part of the body.

As age increased, the fat-to-fat-free mass ratio in the arms and trunk increased (all p < 0.001), but the fat-to-fat-free mass ratio in the legs decreased (p < 0.001). In other words, with age, the proportion of FM increased in the arms and trunk, but the proportion of FM decreased in the legs.

**Discussion**

This study analyzed data from the KNHANES to understand the association between FM or FFM ratios in the arms, legs, and trunk, and the prevalence of CVD-RF. The results of the present study showed that a higher FM ratio in the arms to legs was associated with a higher prevalence of CVD-RF, and a higher FM ratio in the limbs to trunk was associated with lower prevalence of CVD-RF, and a higher FFM ratio in the arms to legs was associated with lower prevalence of CVD-RF.

In previous studies, excessive FM in the legs had a positive effect on metabolic and cardiovascular risk\(^\text{12-14}\). This seems to be because gluteofemoral fat has a strong lipoprotein lipase activity and weak hormone-sensitive lipase activity, lowering low-density lipoprotein cholesterol and TG, and increasing HDL-C\(^\text{24}\). There are no previous studies on the relationship between the arm-to-leg FM ratio and the risk of CVD, but there are some studies that have analyzed the independent effects of FM in the arms, legs, and trunk. In the study that analyzed the risk of CVD according to FM distribution in children and adolescents, FM in the trunk had a positive correlation with low HDL-C, high TG, insulin resistance, and high C-reactive protein, while FM in the leg showed a negative correlation. There was no significant relationship in FM in the arm\(^\text{14}\). In other studies that analyzed the independent relationship between FM in the arms, legs, and trunk and the risk of CVD in adults, FM in the trunk was associated with lipid profile deterioration, and FM in the leg was associated with lipid profile improvement. There was no association between FM in the arm and lipid profile\(^\text{25}\). However, our results demonstrate that the higher the FM ratio in the arms to the legs, the higher the prevalence of CVD-RF. The present study also confirmed that the FM ratio of the arms increases compared to that of the legs with increasing age and BMI (Supplementary Tables S1, S2) and the proportion of FM (fat-to-fat-free mass ratio) increases in the arms and decreases in the legs with increasing age (Supplementary Table S4). Previously, our research group has reported that a high total fat-to-muscle ratio is significantly associated with the prevalence of MetS and insulin resistance\(^\text{26}\). Therefore, taking these factors into account, further studies are required to verify the correlation between FM in the arms and the risk of CVD and the correlation between the arm-to-leg FM ratio and the risk of CVD.

The finding that the higher the FM in the trunk than in the limbs and the lower FFM in the limbs than in the trunk, the higher the prevalence of CVD-RF is consistent with the results of many previous studies showing that abdominal fat increases the risk of CVD\(^\text{6,7,27}\). Therefore, in patients with excessive abdominal fat, reducing body weight and abdominal fat through lifestyle modification on diet and physical activity may reduce the risk of CVD by improving insulin sensitivity and reducing TG, LDL, and BP. Moreover, in the previous study, the higher the total FFM, the lower the risk of MetS\(^\text{28}\). However, there are no previous studies comparing directly to the trunk and limb FFM with the risk of MetS and CVD. In a previous study that analyzed skeletal muscle distribution using magnetic resonance imaging, it was reported that the femoral muscles accounted for the largest proportion of total FFM and that the reduction of leg muscles contributed primarily to the reduction of muscle due to aging\(^\text{29}\). The present study also confirmed that the FM ratio of the trunk increases compared to that of the limbs with increasing age and BMI (Supplementary Tables S1, S2), the FFM ratio of the limbs decreases compared to that of the trunk with increasing age (Supplementary Table S2), and the proportion of FM (fat-to-fat-free mass ratio) increases in the trunk with increasing age (Supplementary Table S4). In addition, the muscle quality of each part of the body is affected not only by aging but also by factors such as physical activity\(^\text{30}\). Therefore, taking these factors into account, further research is needed on the relationship between the limbs-to-trunk FFM ratio and the risk of CVD.

The present study confirmed that the higher the arm-to-leg FFM ratio, the lower the prevalence of MetS. This may be related to the fact that glucose clearance is higher in the arm muscles than in the legs, regardless of insulin resistance, and insulin sensitivity is comparatively better preserved in the arm muscles, especially in patients with type 2 DM\(^\text{31}\). Although there are few studies that directly compared FFM in the arm and the risk of CVD, studies related to arm circumference, which is used as a surrogate marker for the arm muscle mass, indirectly report the relationship between FFM in the arm and a risk of CVD. One previous trial has shown that arm circumference was negatively correlated with all-cause mortality\(^\text{32}\), and another trial reported that arm circumference was negatively correlated with all-cause and CVD mortality\(^\text{33}\). However, there are studies that showed negative effects contrary to this finding. In the study that analyzed the relationship between arm circumference and the risk of CVD, the risk of CVD increased as the arm circumference increased\(^\text{34}\). Another study suggested that arm circumference had a significant positive association with MetS\(^\text{35}\). The inconsistent results between these previous studies may be due to the analysis of FFM without considering the ratio of arms to trunk or legs, or it may be an error caused by indirectly measuring arm FFM with arm circumference. Therefore, taking these factors into account, further studies are required on the relationship between the arm-to-leg FFM ratio and the risk of CVD.

This study is meaningful in that it used large-scale data from the representative KNHANES for 4 years. However, there are several limitations. First, the data based on surveys may have a recall bias. Second, because this is a cross-sectional study, it is not easy to prove a causal relationship to the risk of CVD. Third, although the analysis was conducted by adjusting for age, TEL, smoking, alcohol drinking, PA, education, AMHI, and survey...
year, potential confounding factors that were not considered cannot be ruled out. Finally, the FM and FFM were measured using DEXA, but it was difficult to accurately distinguish between subcutaneous fat, visceral fat, and fat within muscle.

Conclusions
In conclusion, the association between FM or FFM ratios in the arms, legs, and trunk, and the prevalence of CVD-RF was analyzed. The higher the FM in the legs than in the arms, FFM in the arms than in the legs, and FM or FFM in the limbs than in the trunk, the lower the prevalence of CVD-RF. The findings of this study can be used as a guideline for improving body composition to reduce the prevalence of CVD-RF in patients with obesity or sarcopenic obesity.

Data availability
The datasets generated during and/or analysed during the current study are publicly available from the Korea National Health and Nutrition Examination Survey database (URLs: https://knhanes.kdca.go.kr/knhanes/sub03/sub03_02_05.do, https://knhanes.kdca.go.kr/knhanes/eng/index.do).

Received: 27 April 2021; Accepted: 17 August 2021
Published online: 31 August 2021

References
1. Aguilar, M., Bhuket, T., Torres, S., Liu, B. & Wong, R. J. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA 313, 1973–1974 (2015).
2. Tram, B. T., Jeong, B. Y. & Oh, J. K. The prevalence trend of metabolic syndrome and its components and risk factors in Korean adults: results from the Korean National Health and Nutrition Examination Survey 2008–2013. BMC Public Health. 17, 71. https://doi.org/10.1186/s12889-016-3936-6 (2017).
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285, 2486–2497 (2001).
4. Alberti, K. G., Zimmet, P. & Shaw, J. Metabolic syndrome: a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 23, 469–480 (2006).
5. Alexander, J. & Clearfield, M. Cardiovascular disease after menopause: a growing epidemic. Minerva Ginecol. 58, 35–40 (2006).
6. Reaven, G. M. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin N. Am. 95, 875–892 (2011).
7. Piché, M. E., Vasan, S. K., Hodson, L. & Karpe, F. Relevance of human fat distribution on lipid and lipoprotein metabolism and cardiovascular disease risk. Curr. Opin. Lipidol. 29, 285–292 (2018).
8. Srikantian, P. & Karlamangla, A. S. Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition Examination Survey. J. Clin. Endocrinol. Metab. 96, 2898–2903 (2011).
9. Srikantian, P., Hevener, A. L. & Karlamangla, A. S. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS ONE. 5, e18085. https://doi.org/10.1371/journal.pone.0018085 (2010).
10. Ferrara, L. A. et al. Cardiometabolic risk in overweight subjects with or without relative fat-free mass deficiency: the Strong Heart Study. Nutr. Metab. Cardiovasc. Dis. 24, 271–276 (2014).
11. Xing, Z. et al. Association of predicted lean body mass and fat mass with cardiovascular events in patients with type 2 diabetes mellitus. CMAJ 191, E1042–E1048 (2019).
12. Snijder, M. B. et al. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetes Metab. 48, 301–308 (2005).
13. Yang, M. et al. Truncal and leg fat associations with metabolic risk factors among Chinese adults. Asia Pac. J. Clin. Nutr. 25, 798–809 (2016).
14. Stajano, A. E., Gupta, A. K. & Katzmarzyk, P. T. Cardiometabolic risk factors and fat distribution in children and adolescents. J. Pediatr. 164, 560–565 (2014).
15. Tankó, L. B., Bagger, Y. Z., Alexandersen, P., Larsen, P. J. & Christiansen, C. Peripheral adiposity exhibits an independent antiatherogenic effect in elderly women. Circulation 107, 1626–1631 (2003).
16. Ferreira, I. et al. Central fat mass versus peripheral fat and lean mass: opposite (adverse versus favorable) associations with arterial stiffness? The Amsterdam Growth and Health Longitudinal Study. J. Clin. Endocrinol. Metab. 89, 2632–2639 (2004).
17. Hamagami, A. et al. Associations between lower extremity muscle mass and metabolic parameters related to obesity in Japanese obese patients with type 2 diabetes. PeerJ. 3, e942. https://doi.org/10.7717/peerj.942 (2015).
18. Peppa, M. et al. Association of lean body mass with cardiometabolic risk factors in healthy postmenopausal women. Obesity (Silver Spring) 22, 828–835 (2014).
19. Prior, R. M. et al. In vivo validation of whole body composition estimates from dual-energy X-ray absorptiometry. J. Appl. Physiol. 1985(83), 623–630 (1997).
20. Visser, M., Fuerst, T., Lang, T., Salamone, L., & Harris, T. B. Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, Aging, and Body Composition Study—Dual-Energy X-Ray Absorptiometry and Body Composition Working Group. J. Appl. Physiol. (1985); 87, 1513–1520 (1999).
21. Grundy, S. M. et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735–2752 (2005).
22. Lee, S. et al. Cut-off points of waist circumference for defining abdominal obesity in the Korean population. Korean J. Obes. 15, 1–9 (2006).
23. The IPAQ Group. Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ)—short and long forms. https://sites.google.com/site/ipaq/a_home (2011).
24. Manolopoulos, K. N., Karpe, F. & Frayn, K. N. Gluteofemoral body fat as a determinant of metabolic health. Int. J. Obes. (Lond.) 34, 949–959 (2010).
25. Sánchez-López, M. et al. Leg fat might be more protective than arm fat in relation to lipid profile. Eur. J. Nutr. 52, 489–495 (2013).
26. Seo, Y. G., Song, H. J. & Song, Y. R. Fat-to-muscle ratio as a predictor of insulin resistance and metabolic syndrome in Korean adults. J. Clin. Endocrinol. Metab. 11, 710–725 (2020).
27. Kouda, K., Nakamura, H., Fujita, Y., Ohara, K. & Iki, M. Increased ratio of trunk to appendicular fat and increased blood pressure: study of a general population of Hamamatsu children. Circ. J. 76, 2848–2854 (2012).
28. Atlantis, E. et al. Inverse associations between muscle mass, strength, and the metabolic syndrome. *Metabolism* 58, 1013–1022 (2009).
29. Janssen, I., Heymsfield, S. B., Wang, Z. M. & Ross, R. Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. *J. Appl. Physiol.* 1985(89), 81–88 (2000).
30. Yoshiko, A. et al. Muscle quality characteristics of muscles in the thigh, upper arm and lower back in elderly men and women. *Eur. J. Appl. Physiol.* 118, 1385–1395 (2018).
31. Olsen, D. B., Sacchetti, M., DeLa, F., Ploug, T. & Saltin, B. Glucose clearance is higher in arm than leg muscle in type 2 diabetes. *J. Physiol.* 565, 555–562 (2005).
32. Wu, L. W. et al. Mid-arm circumference and all-cause, cardiovascular, and cancer mortality among obese and non-obese US adults: the National Health and Nutrition Examination Survey III. *Sci. Rep.* 7, 2302. https://doi.org/10.1038/s41598-017-02663-7 (2017).
33. Chen, Y. et al. A prospective study of arm circumference and risk of death in Bangladesh. *Int. J. Epidemiol.* 43, 1187–1196 (2014).
34. Hou, Y. et al. Association between mid-upper arm circumference and cardiometabolic risk in Chinese population: a cross-sectional study. *BMJ Open.* 9, e028904. https://doi.org/10.1136/bmjopen-2019-028904 (2019).
35. Shi, J. et al. Large mid-upper arm circumference is associated with metabolic syndrome in middle-aged and elderly individuals: a community-based study. *BMC Endocr. Disord.* 20, 78. https://doi.org/10.1186/s12902-020-00559-8 (2020).

**Author contributions**
S.J.: Formal analysis, data curation, writing- original draft, writing- reviewing and editing. J.P.: Formal analysis, data curation, writing- original draft, writing- reviewing and editing. Y-G.S.: Conceptualization, methodology, formal analysis, data curation, writing- original draft, writing- reviewing and editing.

**Competing interests**
The authors declare no competing interests.

**Additional information**
**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-96874-8.

**Correspondence** and requests for materials should be addressed to Y.-G.S.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021